Evaluation of antibody response to coronavac 600 u/0.5 Ml (sinovac life science, beijing, china) vaccine administration in elderly individuals Antibody response to coronavac in elderly individuals

Aim: In this study, we aimed to evaluate the presence of anti-SARS-CoV-2 antibodies before vaccination and the antibody response after CoronaVac vaccination administered in two doses 28 days apart in elderly individuals over 60 years of age who were planned to be vaccinated against COVID-19. Material and Methods: Antibody levels were evaluated by taking blood samples from participants aged 60 years and over who were vaccinated with inactivated COVID-19 whole virus vaccine in the vaccination outpatient clinic before the first dose of vaccine, 28 days after vaccination (before the second dose), 2 months and 4 months. Results: Of the 81 participants, 51.9% (n=42) were female, 48.1% were male, the mean age was 67.2 +/- 4.6 years, and 48.1% (n=39) had at least one comorbidity. It was found that both seropositivity rates and antibody titres of the participants increased in the first and second months, but in the fourth month, although there was no increase in antibody titres, the mean antibody level decreased compared to the second month. Antibody seropositivity increased both in the 1st month, 2(nd) month and 4th month compared to the pre-vaccination period. Antibody seropositivity at 2 and 4 months was 100.0% in individuals who had all antibody measurements completed at both 2 (n=49) and 4 (n=12) months. Discussion: Vaccination against SARS-CoV-2 with CoronaVac in individuals over 60 years of age induces an effective antibody response, but additional doses are required for the sustainability of the antibody response.